US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Hemab Therapeutics Holdings, Inc.

31.11

+0.05000.16%

Post-market: 31.110.00000.00%19:30 EDT

Volume:354.15K

Turnover:10.90M

Market Cap:1.45B

PE:-17.46

High:31.49

Open:31.49

Low:30.06

Close:31.06

52wk High:55.42

52wk Low:23.00

Shares:46.71M

Float Shares:16.75M

Volume Ratio:0.75

T/O Rate:2.11%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.7820

EPS(LYR):-67.5613

ROE:-46.99%

ROA:-30.11%

PB:3.20

PE(LYR):-0.46

Loading ...

Overview Company News Filings

RA Capital Management acquires Hemab Therapeutics common shares worth $48.7 million

Hemab Therapeutics amends bylaws, ends stockholder action by written consent

Hemab Therapeutics IPO prices at $18, raises USD 346.7 million

Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Stock Track | Hemab Therapeutics Soars 50% on First Trading Day After IPO Pricing

NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM

BRIEF-Hemab Therapeutics Prices Upsized IPO Of 16,750,000 Shares At $18.00 Per Share

Hemab Therapeutics Holdings Inc - Prices IPO of 16,750,000 Shares at $18.00 per Share

THOMSON REUTERS

Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering

Hemab Therapeutics Holdings Inc - Sees IPO of 15,000,000 Common Shares - SEC Filing

THOMSON REUTERS

Biotech Firm Hemab Therapeutics Sets US IPO Target at Up to $212 Million

Hemab Therapeutics Launches Initial Public Offering

MT Newswires Live

Hemab Therapeutics Holdings Inc - Launches IPO of 11,764,706 Common Shares - SEC Filing

THOMSON REUTERS

Hemab Therapeutics Holdings Inc - Estimated IPO Price per Share Between $16.00 and $18.00 - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/COAG/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"COAG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COAG\",,,,,undefined,":{"symbol":"COAG","market":"US","secType":"STK","nameCN":"Hemab Therapeutics Holdings, Inc.","latestPrice":31.11,"timestamp":1790971200000,"preClose":31.06,"halted":0,"volume":354148,"hourTrading":{"tag":"盘后","latestPrice":31.11,"preClose":31.11,"latestTime":"19:30 EDT","volume":4287,"amount":133368.57,"timestamp":1790983803663,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0016097875080489604,"floatShares":16750000,"shares":46705400,"eps":-1.782,"marketStatus":"Market Closed","change":0.05,"latestTime":"10-02 16:00:00 EDT","open":31.49,"high":31.49,"low":30.06,"amount":10900720.416796,"amplitude":0.04604,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.782,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"listingDate":1777608000000,"exchange":"NASDAQ","adjPreClose":31.06,"postHourTrading":{"tag":"盘后","latestPrice":31.11,"preClose":31.11,"latestTime":"19:30 EDT","volume":4287,"amount":133368.57,"timestamp":1790983803663,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7471136336403235},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COAG\",,,,,undefined,":{"symbol":"COAG","floatShares":16750000,"roa":"-30.11%","roe":"-46.99%","lyrEps":-67.56131,"volumeRatio":0.7471136336403235,"shares":46705400,"dividePrice":0,"high":31.49,"amplitude":0.04604,"preClose":31.06,"low":30.06,"week52Low":23.0001,"pbRate":"3.20","week52High":55.42,"institutionHeld":0,"latestPrice":31.11,"eps":-1.782,"divideRate":0,"volume":354148,"delay":0,"ttmEps":-1.782,"open":31.49,"prevYearClose":18,"prevWeekClose":34.74,"prevMonthClose":30.84,"prevQuarterClose":30.84,"fiveDayClose":34.74,"twentyDayClose":44.37,"sixtyDayClose":37.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/COAG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"COAG","fiscalQuarterEnding":"2026/06","expectedEps":-0.63,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-0.8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"COAG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"COAG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1781755200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/COAG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"COAG","date":"2026-10-01","current":-17.457912,"percent":0.951923,"low":-34.170536,"twenty":-29.200872,"median":-22.201677,"eighty":-18.268219,"high":-11.042152,"avg":-23.32509,"sd":5.23427,"marketCap":1440601688},"quantilePoints":[{"date":"2026-05-01","current":-11.042152,"twenty":-11.042152,"median":-11.042152,"eighty":-11.042152,"marketCap":705737088},{"date":"2026-05-08","current":-17.79803,"twenty":-17.79803,"median":-17.407359,"eighty":-17.286354,"marketCap":1137525503},{"date":"2026-05-15","current":-19.616555,"twenty":-19.616555,"median":-17.521449,"eighty":-17.286354,"marketCap":1253752856},{"date":"2026-05-22","current":-18.185245,"twenty":-19.409118,"median":-17.853347,"eighty":-17.293269,"marketCap":1162273533},{"date":"2026-05-29","current":-19.360717,"twenty":-19.450605,"median":-18.046954,"eighty":-17.354117,"marketCap":1237401480},{"date":"2026-06-05","current":-17.56985,"twenty":-19.450605,"median":-18.185245,"eighty":-17.491025,"marketCap":1122941843},{"date":"2026-06-12","current":-18.627775,"twenty":-19.370397,"median":-18.1403,"eighty":-17.515917,"marketCap":1190556995},{"date":"2026-06-18","current":-18.288963,"twenty":-19.294337,"median":-18.002009,"eighty":-17.444006,"marketCap":1168902469},{"date":"2026-06-26","current":-18.159648,"twenty":-19.492093,"median":-18.185245,"eighty":-17.510385,"marketCap":1294673965},{"date":"2026-07-02","current":-21.291074,"twenty":-19.764526,"median":-18.302792,"eighty":-17.540809,"marketCap":1517925825},{"date":"2026-07-10","current":-24.370091,"twenty":-20.501011,"median":-18.714206,"eighty":-17.578148,"marketCap":1737441252},{"date":"2026-07-17","current":-29.172047,"twenty":-21.688778,"median":-18.837687,"eighty":-17.609955,"marketCap":2079791907},{"date":"2026-07-24","current":-30.02369,"twenty":-24.062189,"median":-19.305401,"eighty":-17.650059,"marketCap":2140508940},{"date":"2026-07-31","current":-31.09807,"twenty":-25.689482,"median":-19.512836,"eighty":-17.666654,"marketCap":2217105812},{"date":"2026-08-07","current":-34.170536,"twenty":-29.287346,"median":-19.706444,"eighty":-17.692929,"marketCap":2436154185},{"date":"2026-08-14","current":-30.277152,"twenty":-30.021629,"median":-19.996854,"eighty":-17.818774,"marketCap":2520118712},{"date":"2026-08-21","current":-27.050208,"twenty":-30.064832,"median":-20.629413,"eighty":-17.903131,"marketCap":2251524039},{"date":"2026-08-28","current":-27.774166,"twenty":-30.021629,"median":-21.296443,"eighty":-17.946001,"marketCap":2311782670},{"date":"2026-09-04","current":-24.900782,"twenty":-29.906697,"median":-22.201677,"eighty":-18.108214,"marketCap":2072616631},{"date":"2026-09-11","current":-22.38096,"twenty":-29.479949,"median":-23.509442,"eighty":-18.159648,"marketCap":1862879225},{"date":"2026-09-18","current":-23.132978,"twenty":-29.429728,"median":-22.852375,"eighty":-18.185245,"marketCap":1925473462},{"date":"2026-09-25","current":-20.046337,"twenty":-29.316171,"median":-22.510038,"eighty":-18.288963,"marketCap":1668556819},{"date":"2026-10-01","current":-17.307643,"twenty":-29.200872,"median":-22.201677,"eighty":-18.268219,"marketCap":1440601688}],"updateTime":1790990849595},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"COAG\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633665166","title":"RA Capital Management acquires Hemab Therapeutics common shares worth $48.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633665166","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633665166?lang=en_us&edition=fundamental","pubTime":"2026-05-07 07:17","pubTimestamp":1778109448,"startTime":"0","endTime":"0","summary":"RA Capital Management reported a sharp increase in its Hemab Therapeutics stake, lifting beneficial ownership to 6,314,525 shares held indirectly.Purchases included 2,541,250 shares at USD 18, with additional open-market buys at prices around USD 23.77 to USD 25.Holdings also reflected conversion of preferred stock into 4,838,086 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL32sYQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RA Capital Management acquires Hemab Therapeutics common shares worth $48.7 million","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633538966","title":"Hemab Therapeutics amends bylaws, ends stockholder action by written consent","url":"https://stock-news.laohu8.com/highlight/detail?id=2633538966","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633538966?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:19","pubTimestamp":1777925964,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics Holdings filed amended and restated bylaws effective May 4, 2026, in connection with its IPO.Stockholders can no longer act by written consent in lieu of a meeting.New bylaw framework sets advance-notice procedures for stockholder proposals, director nominations.Bylaws aligned with governance changes in restated charter, including classified board structure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL9Hgswt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633963921","title":"Hemab Therapeutics IPO prices at $18, raises USD 346.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633963921","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633963921?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:01","pubTimestamp":1777924884,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics closed an upsized IPO of 19,262,500 shares of common stock at USD 18 per share.Offering included 2,512,500 shares from full exercise of underwriters’ option; all shares sold by Hemab.Gross proceeds totaled about USD 346.7 million before underwriting discounts, commissions, and offering expenses.Common stock began trading May 1, 2026 on Nasdaq Global Select Market under ticker COAG.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLbCkP37:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","COAG","BK4585","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4588","SG9999014039.USD","LU2210150020.SGD","NDAQ","BK4112","LU2095319765.USD","SG9999014005.SGD","IE00BKPKM429.USD","SG9999014021.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633896630","title":"Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2633896630","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633896630?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:01","pubTimestamp":1777924860,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May  04, 2026 (GLOBE NEWSWIRE) --  Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3287110/0/en/Hemab-Therapeutics-Announces-Closing-of-Upsized-Initial-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IPOS","LENZ","COAG","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146146332","title":"Stock Track | Hemab Therapeutics Soars 50% on First Trading Day After IPO Pricing","url":"https://stock-news.laohu8.com/highlight/detail?id=1146146332","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146146332?lang=en_us&edition=fundamental","pubTime":"2026-05-02 01:07","pubTimestamp":1777655220,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics Holdings Inc (COAG) saw its stock price soar 50.00% intraday on Friday, marking a dramatic debut on the public market.The surge follows the company's announcement that it priced...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632900306","title":"NASDAQ TRADE HALT  REASON NOT AVAILABLE AT 04:00 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2632900306","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632900306?lang=en_us&edition=fundamental","pubTime":"2026-05-01 16:00","pubTimestamp":1777622402,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  REASON NOT AVAILABLE AT 04:00 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nAQN2LXA3F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632747660","title":"BRIEF-Hemab Therapeutics Prices Upsized IPO Of 16,750,000 Shares At $18.00 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2632747660","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632747660?lang=en_us&edition=fundamental","pubTime":"2026-05-01 06:57","pubTimestamp":1777589850,"startTime":"0","endTime":"0","summary":"BRIEF-Hemab Therapeutics Prices Upsized IPO Of 16,750,000 Shares At $18.00 Per ShareApril 30 (Reuters) - Hemab Therapeutics Holdings Inc COAG.O:HEMAB THERAPEUTICS ANNOUNCES PRICING OF UPSIZED INITIAL ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUATBV24:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632660781","title":"Hemab Therapeutics Holdings Inc - Prices IPO of 16,750,000 Shares at $18.00 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2632660781","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632660781?lang=en_us&edition=fundamental","pubTime":"2026-05-01 06:55","pubTimestamp":1777589719,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUATBV24:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632866698","title":"Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2632866698","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632866698?lang=en_us&edition=fundamental","pubTime":"2026-05-01 06:55","pubTimestamp":1777589700,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April  30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3285621/0/en/Hemab-Therapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4007","IPOS","LENZ","COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631638131","title":"Hemab Therapeutics Holdings Inc - Sees IPO of 15,000,000 Common Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2631638131","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631638131?lang=en_us&edition=fundamental","pubTime":"2026-04-30 18:41","pubTimestamp":1777545670,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nFWN41D0T6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131589465","title":"Biotech Firm Hemab Therapeutics Sets US IPO Target at Up to $212 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1131589465","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131589465?lang=en_us&edition=fundamental","pubTime":"2026-04-28 16:06","pubTimestamp":1777363570,"startTime":"0","endTime":"0","summary":"Clinical-stage biotechnology company Hemab Therapeutics Holdings Inc. (COAG.US) is aiming to raise up to $212 million through an initial public offering in the United States. According to a...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1093756325.SGD","BK4599","COAG","BK4585","LU1093756168.USD","NVOX","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4588","NVO","BK4007","NVOH","BK4581","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630331871","title":"Hemab Therapeutics Launches Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2630331871","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630331871?lang=en_us&edition=fundamental","pubTime":"2026-04-27 22:53","pubTimestamp":1777301610,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics said Monday it has launched an initial public offering of about 11.8 million shares of common stock, with pricing estimated to be between $16 and $18 per share.The company granted underwriters the option to purchase up to an additional 1.8 million shares at the initial public offering price.Net proceeds from the offering will be used to initiate a planned phase 3 clinical trial of sutacimig in Glanzmann thrombasthenia and report data from a phase 2 clinical trial of sutacimig in Factor VII deficiency, among others, the company said.Hemab Therapeutics said it has applied to list its common stock on Nasdaq under the symbol \"COAG.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","IPOS","COAG","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630439354","title":"Hemab Therapeutics Holdings Inc - Launches IPO of 11,764,706 Common Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2630439354","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630439354?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:10","pubTimestamp":1777288235,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN41A0PK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630393528","title":"Hemab Therapeutics Holdings Inc - Estimated IPO Price per Share Between $16.00 and $18.00 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393528","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630393528?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:10","pubTimestamp":1777288235,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN41A0PK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":54,"code":"91000000","status":"200"}]}}